# Pizarra — PT-pseudo_b9aa0df93f2a (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_b9aa0df93f2a
Task: 1

Encounter: Urology - outpatient on 04 Feb 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 71-year-old male
  - PSA: 5.5 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.12 ng/mL²
  - PSA velocity: 1.47 ng/mL/yr
  - Prior PSA: 3.8 ng/mL
  - Prostate volume: 49.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8111057 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension
  - Problem list / PMHx: Hypertension
  - Current medication: amlodipine, lisinopril, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 5.5 ng/mL. PI-RADS 5. PSAD 0.12. Prostate volume 49 mL. csPCa 0.81.

Vitals: weight 116 kg, height 175 cm, BMI 37.9, BP 149/83 mmHg, HR 65 bpm. Smoking: Non-smoker.

Chief complaint: Assessment of a 5.5 ng/mL prostate-specific antigen elevation alongside a prior positive biopsy result.

History: A married, 71-year-old warehouse manager who lives alone with his spouse listed as the primary contact. Initial workup began in late 2023 after an elevated prostate-specific antigen was detected. He experiences moderate lower urinary tract symptoms, scoring 15 on the IPSS, mainly due to nocturia and a diminished urinary stream, while explicitly denying haematuria or pelvic discomfort. His medical background includes well-managed hypertension treated with amlodipine, lisinopril, and metoprolol, plus an arthroscopic knee procedure in his forties. He stays physically active by cycling roughly 30 kilometres three times weekly, drinks about two units of alcohol each week, and reports no tobacco use. A recent audiology visit identified mild age-related presbycusis, currently managed with hearing aids. He has voiced significant apprehension about invasive interventions and insists on detailed explanations of every potential step prior to providing consent.

Physical examination: Normal DRE: The prostate is symmetrically enlarged, smooth, and firm, with no palpable nodules or asymmetries. General inspection is unremarkable. Blood pressure measures 149/83 mmHg with a regular heart rate of 65 beats per minute. Abdominal palpation shows no suprapubic tenderness or distended bladder. Peripheral lymphadenopathy and bone tenderness are absent.

Patient info: warehouse manager; Married; Lives alone.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 2 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 15/35 (moderate LUTS).

Recent other appointments: Audiology — hearing test.
Admin: Patient anxious about procedures — allocate extra consult time.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.49 +/- 0.14   (95% CI 0.22-0.77)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.14  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 1.00 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and patient agreement regarding intervention?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with current imaging and trend data, warrants a re-biopsy or deferral, as the initial panel is inconclusive. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the clinical context that the prior biopsy was positive, which fundamentally changes the question from "does he have cancer?" to "is the existing diagnosis confirmed/progressed?" Specifically, it did not weigh the high PI-RADS 5 score (which suggests high likelihood of cancer) against the prior positive biopsy result. It also failed to incorporate the rising PSA velocity (1.47 ng/mL/yr) as a dynamic factor influencing the decision.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.49 +/- 0.14. This suggestion could be wrong because the classifier is operating in a 'discuss' tier, meaning it genuinely cannot distinguish between biopsy and no biopsy based on the input. The guideline criterion explicitly states the decision must come from retrieved documents, which the prior ignored. Furthermore, the prior failed to account for the fact that a prior positive biopsy means the question is not about initial detection but about progression or confirmation, which is a critical context missing from the statistical model.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement regarding intervention?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement regarding intervention?

GUIDELINE ANCHOR
The guideline states that the decision must come from retrieved documents, specifically checking if the prior grade is documented, if the lesion changed against a previous MRI, and whether a surveillance re-biopsy is due.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: Subject: mpMRI Prostate | Institution: LUMC, Leiden | Date: 28 January 2025. A discrete, approximately 12 mm focus is noted within the left peripheral zone at the mid-gland level. PI-RADS 5 lesion in the left mid peripheral zone. csPCa predicted probability 0.8111057.

get_psa_trend
PSA trend: [{"date": "Aug 2023", "val": 1.5}, {"date": "May 2024", "val": 1.2}, {"date": "Feb 2025", "val": 5.5}].

get_previous_notes
Previous notes: Date: 10 Feb 2024, Author: Dr. F. de Boer (GP). Text: Review of escalating prostate-specific antigen values, which climbed from 2.5 ng/mL in August 2023. Because of the prior positive biopsy and the upward trend, a referral to the urology outpatient clinic was scheduled for further evaluation and imaging.

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not explicitly require them, and the retrieved documents did not raise any new laboratory questions.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion in the left mid peripheral zone, 12 mm size.
- PSA trend: Rising trend from 1.2 ng/mL (May 2024) to 5.5 ng/mL (Feb 2025).
- Previous notes: Prior positive biopsy and referral for further evaluation due to rising PSA.

AGAINST sampling this patient now:
- MRI report: No extraprostatic extension, seminal vesicle invasion, or suspicious lymphadenopathy is present.

WHERE THIS LEANS
The retrieved evidence strongly supports the need for further investigation due to a high-risk MRI finding (PI-RADS 5) and a significant, recent rise in PSA velocity.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

REOPENING THE BLACKBOARD (round 2 of 2).

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence (high PI-RADS 5 MRI, significant PSA rise, and prior positive biopsy) strongly leans towards a biopsy, satisfying the requirement set by the guideline criterion.

WHY: the agenda WAS fulfilled and the participants still disagree, so this is a disagreement about INTERPRETATION, not about missing data. DO NOT OPEN ANY FURTHER DOCUMENT - there is nothing left that would settle it, and an extra reveal costs precision for nothing. Instead, go back to what is already on the board and answer one question: which of the two positions is supported by a retrieved finding, and which one is supported only by the visible panel that every participant could already see? Name that finding.

---

# Ronda 2

## [9] GAPS AND DOUBTS (round 2)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the clinical context that the prior biopsy was positive, which fundamentally changes the question from "does he have cancer?" to "is the existing diagnosis confirmed/progressed?". Specifically, it did not weigh the high PI-RADS 5 score (which suggests high likelihood of cancer) against the prior positive biopsy result. It also failed to incorporate the rising PSA velocity (1.47 ng/mL/yr) as a dynamic factor influencing the decision.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.49 +/- 0.14. This suggestion could be wrong because the classifier is operating in a 'discuss' tier, meaning it genuinely cannot distinguish between biopsy and no biopsy based on the input. The guideline criterion explicitly states the decision must come from retrieved documents, which the prior ignored. Furthermore, the prior failed to account for the fact that a prior positive biopsy means the question is not about initial detection but about progression or confirmation, which is a critical context missing from the statistical model.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement regarding intervention?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement regarding intervention?

GUIDELINE ANCHOR
The guideline states that the decision must come from retrieved documents, specifically checking if the prior grade is documented, if the lesion changed against a previous MRI, and whether a surveillance re-biopsy is due.

## [10] EVIDENCE REPORT (round 2)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: Subject: mpMRI Prostate | Institution: LUMC, Leiden | Date: 28 January 2025. A discrete, approximately 12 mm focus is noted within the left peripheral zone at the mid-gland level. PI-RADS 5 lesion in the left mid peripheral zone. csPCa predicted probability 0.8111057.

get_psa_trend
PSA trend: [{"date": "Aug 2023", "val": 1.5}, {"date": "May 2024", "val": 1.2}, {"date": "Feb 2025", "val": 5.5}].

get_previous_notes
Previous notes: Date: 10 Feb 2024, Author: Dr. F. de Boer (GP). Text: Review of escalating prostate-specific antigen values, which climbed from 2.5 ng/mL in August 2023. Because of the prior positive biopsy and the upward trend, a referral to the urology outpatient clinic was scheduled for further evaluation and imaging.

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not explicitly require them, and the retrieved documents did not raise any new laboratory questions.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion in the left mid peripheral zone, 12 mm size.
- PSA trend: Rising trend from 1.2 ng/mL (May 2024) to 5.5 ng/mL (Feb 2025).
- Previous notes: Prior positive biopsy and referral for further evaluation due to rising PSA.

AGAINST sampling this patient now:
- MRI report: No extraprostatic extension, seminal vesicle invasion, or suspicious lymphadenopathy is present.

WHERE THIS LEANS
The retrieved evidence strongly supports the need for further investigation due to a high-risk MRI finding (PI-RADS 5) and a significant, recent rise in PSA velocity.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [11] CLOSING CHECK (round 2)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The agenda was fully met, and the retrieved evidence strongly leans towards a biopsy. The disagreement remains between the statistical prior (No Biopsy) and the evidence (Biopsy), which is a disagreement about interpretation based on the retrieved data.

The chair decides on the record as it stands.

## [12] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: NO BIOPSY   (confidence: borderline)

The statistical prior suggested no biopsy (p=0.49), while the retrieved evidence strongly leaned toward biopsy due to the PI-RADS 5 finding and the rising PSA trend. The guideline criterion abstained because the retrieved documents did not provide a definitive reason to overturn the prior, leaving a split between the statistical prediction and the evidence. Since no retrieved document explicitly documented a prior grade or lesion change that would definitively change the management, I defer to the lack of documented justification for sampling.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
